These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8210642)

  • 81. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 83. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Recent Results Cancer Res; 1993; 131():223-38. PubMed ID: 8210642
    [No Abstract]   [Full Text] [Related]  

  • 85. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
    Lotzová E
    Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Natural killer cells in haematopoietic stem cell transplantation.
    Lowdell MW
    Transfus Med; 2003 Dec; 13(6):399-404. PubMed ID: 14651745
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
    Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
    Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
    [No Abstract]   [Full Text] [Related]  

  • 88. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
    Malkovska V; Sondel PM
    J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Interleukin-2 in autologous bone marrow transplantation.
    Charak BS
    Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.
    Klingemann HG
    Leuk Lymphoma; 1992 Dec; 8(6):421-9. PubMed ID: 1284296
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Interleukin-2 in bone marrow transplantation: preclinical studies.
    Charak BS; Choudhary GD; Tefft M; Mazumder A
    Bone Marrow Transplant; 1992 Aug; 10(2):103-11. PubMed ID: 1326364
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Agar capillary clonogenic microassays for cellular immunocytotoxic activities in human leukaemia and lymphoma.
    Maurer HR; Hassan HT
    Leuk Lymphoma; 1993 Mar; 9(4-5):305-13. PubMed ID: 7688626
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.